Broide David H
Department of Medicine, University of California San Diego, 9500 Gilman Drive, MC 0635, La Jolla, CA 92093, USA.
Curr Allergy Asthma Rep. 2005 May;5(3):182-5. doi: 10.1007/s11882-005-0035-7.
Therapeutic strategies based on the use of immunostimulatory sequences of DNA containing a CpG motif (also known as ISS DNA, or CpG DNA) are focused on minimizing the allergenicity of immunotherapy while improving its effectiveness. Several ISS DNA-based methods of immunization (ISS DNA alone, ISS DNA conjugated to a protein allergen) have shown promise in animal models of asthma, and some of these ISS DNA-based therapies have entered clinical trials. These ongoing clinical trials will help to determine whether any of these ISS DNA-based therapies are safe and effective to use in subjects with allergic rhinitis and asthma.
基于使用含CpG基序的DNA免疫刺激序列(也称为ISS DNA或CpG DNA)的治疗策略,旨在在提高免疫疗法有效性的同时,尽量降低其致敏性。几种基于ISS DNA的免疫方法(单独使用ISS DNA、与蛋白质过敏原偶联的ISS DNA)在哮喘动物模型中已显示出前景,其中一些基于ISS DNA的疗法已进入临床试验阶段。这些正在进行的临床试验将有助于确定这些基于ISS DNA的疗法是否对过敏性鼻炎和哮喘患者安全有效。